CRESSKILL, N.J., July 22, 2008 (PRIME NEWSWIRE) -- Vascular Therapies LLC, a vascular combination device company, today announced that it has appointed Samuel M. Liang as President and Chief Executive Officer effective immediately. Sriram S. Iyer, M.D., the company's founder, will remain as Chairman of the Board.
Liang, 45, joins Vascular Therapies from Cordis, a Johnson & Johnson company, where most recently he was Vice President, Worldwide Commercial Operations. During over 24 years with Cordis he has held positions of increasing responsibility and leadership in the areas of strategy, manufacturing, regulatory affairs, new product development, field sales, corporate accounts, marketing, and general management.
``Sam brings wide-ranging experience, both domestic and international, in diversified medical devices and combination products. It's worth noting that, as Worldwide Vice President of the Cypher Programs and Global Stent Franchise, he was responsible for all aspects of the company's drug-eluting stent franchise and initiatives. This included the commercialization and launch of the first- and second-generation drug-eluting stent products, which earned an unprecedented incremental U.S. reimbursement that coincided with the product launch,'' said Dr. Iyer. ``We are delighted Sam has accepted this position and welcome him to the Vascular Therapies family.''
Added Liang: ``It is an honor to join Vascular Therapies. I am energized and excited to join Dr. Iyer and his dynamic and talented team that is developing solutions that will have immediate and significant impact in healthcare by addressing areas of unmet clinical need.''
Liang earned a Masters in Management from the Kellogg Graduate School of Management at Northwestern University and a B.S.E. in mechanical engineering and material sciences from Duke University.
About Vascular Therapies
Vascular Therapies is a vascular device company whose innovative research and development has lead to the creation of a drug eluting combination product platform technology, the Coll-Rtm. In early human clinical studies the Coll-Rtm demonstrated safety and extended follow-up outcomes support efficacy marked by significant improvement in patency of peripheral vascular and hemodialysis AV Grafts.
Vascular Therapies retained Heidrick & Struggles International, Inc. (Nasdaq:HSII), the world's premier executive search and leadership consulting firm, to conduct this successful search.
Vascular Therapies, LLC
Puneet Sapra, Vice President, Product and Business Strategy
(201) 227 8911
Fax: (201) 227-8997
Source: Vascular Therapies